Planned and Unplanned Mid-Study Updates Pose Major Challenge to Clinical Trial Timelines, According to Tufts Center for the Study of Drug Development Tufts Center for the Study of Drug Development Analysis Finds Larger Pharmaceutical Companies Experience Longer Delays due to Mid-Study Updates BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Planned...

Transition to Decentralized Clinical Trials during the Coronavirus Pandemic Is far More Nuanced than Expected, According to Tufts Center for the Study of Drug Development BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- The coronavirus pandemic has facilitated rapid adoption of decentralized clinical trial execution, with more than half of all global clinical trials now...

New Anti-infective Drugs Had a 14% Speed Advantage vs. Other Drugs During 2000-19, According to Tufts Center for the Study of Drug Development BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- New anti-infective drugs that won marketing approval in the United States during the last two decades took 14% less time to undergo clinical trials and...